Netherlands Cancer Institute, Principal Investigator
Ton Schumacher is Principal Investigator at The Netherlands Cancer Institute, and Professor of Immunotechnology at Leiden University. Research of his lab focuses on the development of novel technologies with which T cell responses can be measured or manipulated, and the subsequent use of these technologies to understand how T cells can recognize and destroy human cancer. Work over the past years has described the role of the ‘cancer neo-antigens’ that are formed as a consequence of DNA damage as a major ingredient to effective immunotherapy of human cancer.
Schumacher is recipient of, amongst others, the Amsterdam Inventor Award (2010), Queen Wilhelmina Cancer Research Award (2014), San Salvatore Award (2014), Meyenburg Cancer Research Award (2015), and William B. Coley Award (2016). Schumacher is also co-founder of 3 biotechs that focus on the development of novel cancer immunotherapeutics.
California Institute of Technology, Professor
Jim Heath is the Elizabeth Gilloon Professor and Professor of Chemistry at Caltech, and co-leads the Cancer Nanotechnology Program within the JCCC. He has directed the National Cancer Institute funded NSB Cancer Center since 2005, which is a NCI-funded CancerCenter for Nanotechnology Excellence that is a joint Caltech/UCLA program focused on translating new therapeutic and diagnostic technologies from benchtop to bedside. Heath also co-Directs the UCLA Parker Institute for Cancer Immunotherapy. He received his Ph.D. from Rice University. He was a member of the research staff at IBM Watson Labs before joining the faculty at UCLA in 1994, and then moving to Caltech in 2003. Heath’s group works on the development and application of single cell and molecular methods for fundamental cancer biology and translational oncology applications.
Rob de Boer
University of Utrecht, Professor
Rob de Boer is head of the Theoretical Biology group and an expert in Computational Biology. The primary goal of this group is to use and develop formal approaches to better understand the functioning and evolution of complex biological systems. The focus of De Boer in the Theoretical Biology group is Quantitative Immunology. After his post-doc at the Los Alamos National Laboratory in New Mexico, he joined the Theoretical Biology & Bioinformatics group at Utrecht University (The Netherlands) in 1992, running an independent research group on modeling the immune system. He received the Dutch Innovative research VICI grant in 2004, and became Full Professor in Theoretical Immunology. De Boer was promoted to Full Professor in Theoretical Biology at Utrecht University in 2009.
The focus of the De Boer group on modeling and bioinformatics helps to interpret experimental data in a quantitative manner, and to suggest novel experiments allowing for more conclusive insights. Several examples are dynamics of lymphocytes, responses to viruses and the killing rates of cytotoxic T cells.
MRC laboratory, University College London, Group Leader
Sophie Acton is a group leader at the MRC laboratory for Molecular Cell biology at University College London, and a Cancer Research UK Career Development Fellow. Her lab works on the communication that occurs between immune cells and fibroblastic stroma, to control immune responses, and to influence anti-tumour immunity. Dr Acton studied Pharmacology at the University of Bath, and then undertook a PhD working on mechanisms of metastasis in melanoma. Following this she moved into the field of immunology and working on mechanisms of dendritic cell trafficking at Harvard medical school, and on mechanisms of lymph node expansion at the LRI in London. Dr Acton was a recipient of a Henry Wellcome postdoctoral fellowship and and currently a L’Oreal/UNESCO for Women in Science Fellow.
Leiden University, Emeritus Professor
Professor Cornelis (Kees) JM Melief is emeritus professor of internal medicine specialized in “immunohematology” at Leiden University. Since 2011 he is emeritus professor at LUMC and Chief Scientific Officer (CSO) of ISA Pharmaceuticals, a biotech company specializing in development of synthetic vaccines.
He received his Ph.D. degree in 1967 from the University of Amsterdam, where he also received his M.D. degree in 1970. He spent two years (1973/1974) as a postdoctoral fellow at the New England Medical Center and Dana Farber Cancer Center (Harvard) in Boston. In 1975 he became a staff member of the Netherlands Red Cross Blood Transfusion Service, heading a newly established department of cell-mediated immunology. In 1985 he became head of the Dept. of Tumor Immunology at the Netherlands Cancer Institute in Amsterdam. In 1991 he became head of the Dept.of immunohematology and blood transfusion at Leiden University Medical Center, also establishing and heading the tumor immunology group in the department.
Of his many contributions to basic immunology, including work in mouse models, and clinical immunology, the most striking highlights are the eradication of large vascularized mouse tumors by adoptive transfer of cytotoxic T lymphocytes directed against an oncogene-encoded protein as well as the discovery that T cell help for cytotoxic T lymphocyte induction involves cognate interaction between CD40 ligand on T helper cells and CD40 on Dendritic Cells. This is a major novel pathway of cytotoxic T lymphocyte induction in non-inflammatory conditions.
Jolanda de Vries
Radboud University, Professor
Jolanda M. de Vries is Professor of Translational Tumour Immunology at the Radboud UMC in Nijmegen. She obtained her PhD degree at the University of Utrecht in 1997 and afterwards became a postdoctoral researcher Nijmegen. Jolanda is a researcher who believes in the potential of the immune system to tackle cancer without significant side effects. It is her scientific ambition to translate results from the laboratory as soon as possible to clinical applications.
Prof. Dr. De Vries received the Huibregtsen award on October 9th 2017 during the night of Science & Society for her research on natural dendritic cellular vaccination. She is currently the only scientist in the world researching this way of battling cancer. Treatment costs of cancer patients with these natural dendritic cellular vaccines are already covered by the Dutch basic health insurance.
Sander van Kasteren
Leiden University, Group Leader
Sander van Kasteren is assistant professor in the field of chemical immunology. He received his Master’s degree in Chemistry from the University of Edinburgh in 2001, before to moving to Oxford for his PhD under the tutelage of Prof. Benjamin G. Davis. Here he worked on the chemical modification of proteins for immune diagnostics. After obtaining his PhD in 2007, he obtained a Henry Wellcome Fellowship to move to the group of Colin Watts in Dundee to study antigen processing and presentation. He then moved to back to the Netherlands to work with professors Huib Ovaa and Jacques Neefjes at the NKI on an NWO Veni-grant before starting his own group in Leiden in 2012. His current research interest are on the development of new approaches to study degradative events in the immune system based on bioorthogonal chemistry. He has developed imaging techniques that allow the visualization of bioorthogonally labelled bacteria, vaccines and auto-antigens within immune cells, even as they are being degraded. Using similar approaches he is also attempting to measure the speed with which vaccines are processed by the immune system. Using these techniques he aims to understand the factors that govern why an adaptive immune response is mounted against specific peptide sequences and not against others.
Roche Innovation Center Zurich, Department Head
Christian Klein, Distinguished Scientist is Head of Oncology Programs and Department Head Cancer Immunotherapy Discovery at the Roche Innovation Center Zurich, Roche Pharmaceutical Research & Early Development specialized in engineering of (bispecific) antibodies and the discovery, validation and preclinical development of antibody-based cancer immunotherapy.
During his >15 years at Roche he has made major contributions as a research project team leader to the development and approval of obinutuzumab, to the preclinical development of six clinical stage bispecific antibodies/immunocytokines and the development of Roche’s CrossMAb technology and the immunocytokine and T cell bispecific antibody platforms. He also contributed to research on MDM2 inhibitors (Nutlins), and lead(s) research on preclinical antibody-based cancer immunotherapy projects and combination therapy.
The Hebrew University of Jerusalem, Professor and M.D.
Prof. Nissim Benvenisty is the Herbert Cohn Chair in Cancer Research and the Director of The Azrieli Center for Stem Cells and Genetic Research at the Hebrew University. He earned his M.D. and Ph.D. degrees from the Hebrew University, and conducted postdoctoral studies at Harvard University. Prof. Benvenisty’s research projects focus on stem cell biology, tissue engineering, human genetics, and cancer research. Prof. Benvenisty presents the issue of human embryonic stem cells in many international conferences, and gave testimonies before the US Senate and the European Union. He was awarded several prizes among them the Foulkes Prize (London), the Hestrin Prize, the Teva Prize, the Kaye Prize and the Milken Prize.
… and more to be announced!